David Bains, MD
Nephrology · Huntsville, ALNPI 1447419288
Payments from drug & device makers
Across 274 payments — averaging $3124.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$760K
- Vertex$92K
- Vifor Pharma, Inc.$756
- Novartis$534
- Bayer$427
- Calliditas Therapeutics US Inc.$384
- plus $3K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 39 | $759,659 |
| Vertex | 1 | $91,733 |
| Vifor Pharma, Inc. | 40 | $756 |
| Novartis | 21 | $534 |
| Bayer | 14 | $427 |
| Calliditas Therapeutics US Inc. | 14 | $384 |
| Otsuka America Pharmaceutical, Inc. | 20 | $359 |
| Amgen(2 entities) | 19 | $344 |
| OPKO Pharmaceuticals, LLC | 18 | $287 |
| GSK | 12 | $269 |
| Travere Therapeutics, Inc. | 21 | $197 |
| Ardelyx, Inc. | 5 | $197 |
| Boehringer Ingelheim | 9 | $190 |
| Novo Nordisk | 8 | $173 |
| Akebia Therapeutics Inc | 5 | $111 |
| Ultragenyx Pharmaceutical Inc. | 5 | $106 |
| Aurinia Pharma U.S., Inc. | 4 | $103 |
| Lilly USA, LLC | 3 | $62 |
| Apellis Pharmaceuticals, Inc. | 2 | $36 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Fresenius USA Marketing, Inc. | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Cormedix Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Medtronic | 1 | $11 |
How this compares
$856,185 in reported general payments places this provider in the 95th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Huntsville
- David TietjenHuntsville$2.6M
- Michael QuadriniHuntsville$1.3M
- Carlo CastilloHuntsville$461K
- James SmelserHuntsville$172K
- Roger CoomerHuntsville$93K
- Todd BroomeHuntsville$7K
- Heather HaleyHuntsville$6K
- Saad RahmanHuntsville$6K
- Dana RizkBirmingham$2.6M
- Eric WallaceBirmingham$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.